Insmed Inc

IM8N

Company Profile

  • Business description

    Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

  • Contact

    700 US Highway 202/206
    BridgewaterNJ08807
    USA

    T: +1 908 977-9900

    E: [email protected]

    https://www.insmed.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    1,271

Stocks News & Analysis

stocks

Goodman earnings: All eyes on data center progress

Our view after results.
stocks

Earnings winners: BHP, NAB & TLS lead the pack

The winners of this weeks earnings that saw strong investor backing
stocks

Walmart earnings: Growth in digital buoys margin amid consumer trade-down

We think Walmart stock is significantly overvalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,303.209.300.10%
CAC 408,515.49116.711.39%
DAX 4025,260.69217.120.87%
Dow JONES (US)49,588.98193.820.39%
FTSE 10010,686.8959.850.56%
HKSE26,413.35292.59-1.10%
NASDAQ22,875.73193.000.85%
Nikkei 22556,825.70642.13-1.12%
NZX 50 Index13,308.52135.68-1.01%
S&P 5006,905.3643.470.63%
S&P/ASX 2009,081.4017.000.19%
SSE Composite Index4,082.0751.95-1.26%

Market Movers